Effective tissue procurement and utilization is vital for meaningful translational research activities. The Tissue Procurement and Hematopathology Core will work with each SPORE project and the Biostatistics and Data Management Core to ensure efficient and highly-coordinated procurement, use and storage of blood and bone marrow samples. The Core will obtain and maintain a repository of blood samples (including peripheral blood, bone marrow biopsies, and bone marrow aspirates) for laboratory use, with an effective coding system for all laboratory specimens to ensure patient confidentiality and prevent experimental bias. Continuous communication between the investigators, research nurses, biostatisticians and hematopathologists, as well as standardized operating procedures for activities will provide for optimal tissue collection and accurate processing, analysis and storage of each sample. Thus, the functions of the Pathology and Tissue Core are to facilitate acquisition, preservation, analysis and dispersal of clinical samples and to provide hematopathologic characterization and specimens for all project investigators. The Tissue Procurement and Hematopathology Core has the following objectives: ? Develop and maintain a repository of blood and bone marrow specimens, including intact cells, serum, cellular DNA, RNA and protein, from patients with leukemia and MDS (including patients who are newly diagnosed, in remission and/or in relapse) receiving care or evaluation at M.D. Anderson Cancer Center. Distribute tissue specimens to SPORE investigators for analysis and provide expertise in the interpretation of studies performed on tissue sections within SPORE projects Provide comprehensive histologic characterization of blood and marrow samples used in SPORE projects, including specimens from patients entered onto clinical protocols. ? Provide stock and customized Reverse Phase Protein Arrays to Spore researchers. ? Maintain a comprehensive, prospective interactive database with detailed clinical and pathologic data for patients with leukemia and MDS receiving care or evaluation at M.D. Anderson Cancer Center ? Facilitate inter-SPORE collaborations through sharing of blood and marrow resources. Lay Abstract: Effective tissue procurement and utilization is vital for meaningful translational research activities. The Tissue Procurement and Hematopathology Core will work with each SPORE project and the Biostatistics and Data Management Core to ensure efficient and highly-coordinated procurement, use and storage of blood and bone marrow samples

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA100632-07
Application #
7826874
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-05-01
Budget End
2010-04-30
Support Year
7
Fiscal Year
2009
Total Cost
$254,153
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Cortes, Jorge E; Tallman, Martin S; Schiller, Gary J et al. (2018) Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood 132:598-607
Ohanian, Maro; Rozovski, Uri; Kanagal-Shamanna, Rashmi et al. (2018) MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma :1-12
Boddu, P; Jorgensen, J; Kantarjian, H et al. (2018) Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia 32:241-244
Yan, Fangrong; Zhu, Huihong; Liu, Junlin et al. (2018) Design and inference for 3-stage bioequivalence testing with serial sampling data. Pharm Stat 17:458-476
Kelly, Andrew D; Madzo, Jozef; Madireddi, Priyanka et al. (2018) Demethylator phenotypes in acute myeloid leukemia. Leukemia 32:2178-2188
Levis, Mark J; Perl, Alexander E; Altman, Jessica K et al. (2018) A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv 2:825-831
Shah, Maitri Y; Ferracin, Manuela; Pileczki, Valentina et al. (2018) Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28:432-447
Masarova, Lucia; Verstovsek, Srdan; Hidalgo-Lopez, Juliana E et al. (2018) A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood 132:1664-1674
Good, Charly Ryan; Panjarian, Shoghag; Kelly, Andrew D et al. (2018) TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer. Cancer Res 78:4126-4137
Choi, Sangbum; Kang, Sangwook; Huang, Xuelin (2018) Smoothed quantile regression analysis of competing risks. Biom J 60:934-946

Showing the most recent 10 out of 487 publications